Journal article

Emergence of artemisinin-resistant Plasmodium falciparum with kelch13 C580Y mutations on the island of New Guinea

Olivo Miotto, Makoto Sekihara, Shin-Ichiro Tachibana, Masato Yamauchi, Richard D Pearson, Roberto Amato, Sonia Goncalves, Somya Mehra, Rintis Noviyanti, Jutta Marfurt, Sarah Auburn, Ric N Price, Ivo Mueller, Mie Ikeda, Toshiyuki Mori, Makoto Hirai, Livingstone Tavul, Manuel W Hetzel, Moses Laman, Alyssa E Barry Show all

PLOS PATHOGENS | PUBLIC LIBRARY SCIENCE | Published : 2020

Abstract

The rapid and aggressive spread of artemisinin-resistant Plasmodium falciparum carrying the C580Y mutation in the kelch13 gene is a growing threat to malaria elimination in Southeast Asia, but there is no evidence of their spread to other regions. We conducted cross-sectional surveys in 2016 and 2017 at two clinics in Wewak, Papua New Guinea (PNG) where we identified three infections caused by C580Y mutants among 239 genotyped clinical samples. One of these mutants exhibited the highest survival rate (6.8%) among all parasites surveyed in ring-stage survival assays (RSA) for artemisinin. Analyses of kelch13 flanking regions, and comparisons of deep sequencing data from 389 clinical samples f..

View full abstract

Grants

Awarded by Japan Society for the Promotion of Science and Foundation of Strategic Research Projects in Private Universities


Awarded by Ministry of Education, Culture, Sports, Science, and Technology of Japan


Awarded by Japan Agency for Medical Research and Development


Awarded by Global Health Innovative Technology Fund


Awarded by National Health and Medical Research Council of Australia


Awarded by Australian Centre for Research Excellence on Malaria Elimination


Awarded by Wellcome Trust


Awarded by Bill AMP; Melinda Gates Foundation


Awarded by Medical Research Council of the UK


Funding Acknowledgements

This study was supported by: -Grants-inaid for scientific research from the Japan Society for the Promotion of Science and Foundation of Strategic Research Projects in Private Universities (TM; https://www.jsps.go.jp/english/e-grants/; 26460515, 26305015, 17H04074, 18KK0231) The Ministry of Education, Culture, Sports, Science, and Technology of Japan (TM; https://www.mext.go.jp/en/; S0991013) -Japan Agency for Medical Research and Development (TM; https://www.amed.go.jp/en/; JP15km0908001) -The Global Health Innovative Technology Fund (TM; https://www.ghitfund.org/; G2015-210) -The Global Fund to Fight AIDS, Tuberculosis and Malaria (MWH, AEB; https://www.theglobalfund.org/en/) -The National Health and Medical Research Council of Australia (AEB; https://www.nhmrc.gov.au/; GNT1027108, APP 1131932) -The Australian Centre for Research Excellence on Malaria Elimination (SA; https://www.acreme.org.au/; APP 1134989) -The Australian Government Department of Foreign Affairs and Trade through the Tropical Disease Research Regional Collaboration Initiative (AEB; https://indopacifichealthsecurity.dfat.gov.au/TDRRCI) The Victorian State Government Operational Infrastructure Support (AEB; https://www2.health.vic.gov.au/about/clinical-trials-and-research/operational-infrastructure-support) -The Wellcome Trust (DPK; https://wellcome.ac.uk/; 206194, 090770/Z/09/Z) -The Bill & Melinda Gates Foundation (OM, DPK; https://www.gatesfoundation.org/; OPP11188166) -The Medical Research Council of the UK (DPK; https://mrc.ukri.org/; G0600718) The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.